📊 IOVA Key Takeaways
Is IOVA a Good Investment? Thesis Analysis
Iovance is burning substantial cash with operating losses of -$403.4M and free cash flow of -$336.2M despite 60.6% YoY revenue growth, indicating the company is not approaching profitability. The severe negative margins (-153% operating, -148% net) and declining net income quality relative to revenue growth suggest fundamental unit economics problems in the business model. With only $163.1M in cash and current burn rate, runway is critically constrained.
Why Buy IOVA? Key Strengths
- Strong revenue growth of 60.6% YoY demonstrates market demand for therapies
- Solid liquidity position with 3.20x current ratio and $163.1M cash reserves
- Reasonable balance sheet structure with 0.00x debt-to-equity and $698.6M stockholders equity
- 16 insider Form 4 filings in last 90 days show ongoing management participation
IOVA Investment Risks to Consider
- Extreme cash burn: -$336.2M free cash flow with only $163.1M cash implies <6 months of runway without additional financing
- Deteriorating profitability metrics: operating margin of -153% with net losses expanding, indicating inability to scale efficiently
- High cash burn relative to revenue (127.6% negative FCF margin) suggests core business model may not be viable at current scale
- Growing operating losses of -$403.4M despite strong top-line growth indicates severe unit economics challenges
- Unsustainable burn rate requires continuous dilutive financing to remain solvent
Key Metrics to Watch
- Operating cash flow trend and time to cash flow breakeven
- Cash balance depletion rate relative to monthly burn
- Gross margin improvement as manufacturing scales
- Path to GAAP profitability or evidence of unit-level economics improvement
- Financing activities and dilution from capital raises
IOVA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.20x current ratio provides a solid financial cushion.
IOVA Profitability Ratios
IOVA vs Healthcare Sector
How IOVANCE BIOTHERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IOVA Overvalued or Undervalued?
Based on fundamental analysis, IOVANCE BIOTHERAPEUTICS, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IOVA Balance Sheet & Liquidity
IOVA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IOVANCE BIOTHERAPEUTICS, INC.'s revenue has grown significantly by 22,062% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.89 indicates the company is currently unprofitable.
IOVA Growth Metrics (YoY)
IOVA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $58.6M | -$83.5M | N/A |
| Q2 2025 | $31.1M | -$97.1M | $-0.33 |
| Q1 2025 | $715.0K | -$113.0M | $-0.36 |
| Q3 2024 | $469.0K | -$83.5M | $-0.28 |
| Q2 2024 | $238.0K | -$97.1M | $-0.34 |
| Q1 2024 | $715.0K | -$107.4M | $-0.42 |
| Q3 2023 | $469.0K | -$99.6M | $-0.46 |
| Q2 2023 | $238.0K | -$99.3M | $-0.47 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IOVA Capital Allocation
IOVA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IOVANCE BIOTHERAPEUTICS, INC. (CIK: 0001425205)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IOVA
What is the AI rating for IOVA?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IOVA's key strengths?
Claude: Strong revenue growth of 60.6% YoY demonstrates market demand for therapies. Solid liquidity position with 3.20x current ratio and $163.1M cash reserves.
What are the risks of investing in IOVA?
Claude: Extreme cash burn: -$336.2M free cash flow with only $163.1M cash implies <6 months of runway without additional financing. Deteriorating profitability metrics: operating margin of -153% with net losses expanding, indicating inability to scale efficiently.
What is IOVA's revenue and growth?
IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $263.5M.
Does IOVA pay dividends?
IOVANCE BIOTHERAPEUTICS, INC. does not currently pay dividends.
Where can I find IOVA SEC filings?
Official SEC filings for IOVANCE BIOTHERAPEUTICS, INC. (CIK: 0001425205) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IOVA's EPS?
IOVANCE BIOTHERAPEUTICS, INC. has a diluted EPS of $-1.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IOVA a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, IOVANCE BIOTHERAPEUTICS, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IOVA stock overvalued or undervalued?
Valuation metrics for IOVA: ROE of -56.0% (sector avg: 15%), net margin of -148.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IOVA stock in 2026?
Our dual AI analysis gives IOVANCE BIOTHERAPEUTICS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IOVA's free cash flow?
IOVANCE BIOTHERAPEUTICS, INC.'s operating cash flow is $-302.4M, with capital expenditures of $33.8M. FCF margin is -127.6%.
How does IOVA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -148.4% (avg: 12%), ROE -56.0% (avg: 15%), current ratio 3.20 (avg: 2).